


**COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS**  
(Currently amended claims showing deletions by ~~strikethrough~~  
and additions by underlining)

1 (currently amended) : A compound of formula I,



(I)

wherein

n1 is  $\theta$  1;



X is, independently for each occurrence,  $(CHR^{11})_{n3}(CH_2)_{n4}Z(CH_2)_{n5}$ ;

Z is O,  $N(R^{12})$ , S, or a bond;

n3 is, independently for each occurrence, 0 or 1;

n4 and n5 each is, independently for each occurrence, 0, 1, 2, or 3;

Y is, independently for each occurrence, CO,  $CH_2$ , CS, or a bond;



$R^2$ ,  $R^{11}$ , and  $R^{12}$  each is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of  $(C_{1-6})$ alkyl and

Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 3

aryl, wherein said optionally substituted moiety is optionally substituted with one or more of  $R^8$  or  $R^{30}$ ;  
 $R^3$  is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of  $(C_{1-6})$ alkyl,  $(C_{2-6})$ alkenyl,  $(C_{2-6})$ alkynyl,  $(C_{3-6})$ cycloalkyl,  $(C_{3-6})$ cycloalkyl  $(C_{1-6})$ alkyl,  $(C_{5-7})$ cycloalkenyl,  $(C_{5-7})$ cycloalkenyl  $(C_{1-6})$ alkyl, aryl, aryl  $(C_{1-6})$ alkyl, heterocyclyl, and heterocyclyl  $(C_{1-6})$ alkyl, wherein said optionally substituted moiety is optionally substituted with one or more  $R^{30}$ ;  
 $R^4$  and  $R^5$  each is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of  $(C_{1-6})$ alkyl,  $(C_{3-6})$ cycloalkyl, aryl, and heterocyclyl, wherein said optionally substituted moiety is optionally substituted with one or more  $R^{30}$ , wherein each said substituent is independently selected, or  $R^4$  and  $R^5$  can be taken together with the carbons to which they are attached to form aryl;  
 $R^6$  is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of  $(C_{1-6})$ alkyl,  $(C_{2-6})$ alkenyl,  $(C_{3-6})$ cycloalkyl,  $(C_{3-6})$ cycloalkyl  $(C_{1-6})$ alkyl,  $(C_{5-7})$ cycloalkenyl,  $(C_{5-7})$ cycloalkenyl  $(C_{1-6})$ alkyl, aryl, aryl  $(C_{1-6})$ alkyl, heterocyclyl, and heterocyclyl  $(C_{1-6})$ alkyl, wherein said optionally substituted moiety is optionally substituted with one or more substituents each independently selected from the group consisting of OH,  $(C_{1-6})$ alkyl,  $(C_{1-6})$ alkoxy,  $-N(R^8R^9)$ ,  $-COOH$ ,  $-CON(R^8R^9)$ , and halo, where  $R^8$  and  $R^9$  each is, independently for each occurrence, H,  $(C_{1-6})$ alkyl,  $(C_{2-6})$ alkenyl,  $(C_{2-6})$ alkynyl, aryl, or aryl  $(C_{1-6})$ alkyl;  
 $R^7$  is, independently for each occurrence, H,  $=O$ ,  $=S$ , or an optionally substituted moiety selected from the group consisting of  $(C_{1-6})$ alkyl,  $(C_{2-6})$ alkenyl,  $(C_{3-6})$ cycloalkyl,


Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 4

(C<sub>3-6</sub>)cycloalkyl(C<sub>1-6</sub>)alkyl, (C<sub>5-7</sub>)cycloalkenyl, (C<sub>5-7</sub>)cycloalkenyl(C<sub>1-6</sub>)alkyl, aryl, aryl(C<sub>1-6</sub>)alkyl, heterocyclyl, and heterocyclyl(C<sub>1-6</sub>)alkyl, wherein said optionally substituted moiety is optionally substituted with one or more substituents each independently selected from the group consisting of OH, (C<sub>1-6</sub>)alkyl, (C<sub>1-6</sub>)alkoxy, -N(R<sup>8</sup>R<sup>9</sup>), -COOH, -CON(R<sup>8</sup>R<sup>9</sup>), and halo;

R<sup>10</sup> is C;

R<sup>21</sup> is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C<sub>1-6</sub>)alkyl and aryl(C<sub>1-6</sub>)alkyl, wherein said optionally substituted moiety is optionally substituted with one or more substituents each independently selected from the group consisting of R<sup>8</sup> and R<sup>30</sup>;

R<sup>22</sup> is H, (C<sub>1-6</sub>)alkylthio, (C<sub>3-6</sub>)cycloalkylthio, R<sup>8</sup>-CO-, or a substituent according to the formula



R<sup>24</sup> and R<sup>25</sup> each is, independently for each occurrence, H, (C<sub>1-6</sub>)alkyl, or aryl(C<sub>1-6</sub>)alkyl;


R<sup>30</sup> is, independently for each occurrence, (C<sub>1-6</sub>)alkyl, -O-R<sup>8</sup>, -S(O)<sub>n6</sub>R<sup>8</sup>, -S(O)<sub>n7</sub>N(R<sup>8</sup>R<sup>9</sup>), -N(R<sup>8</sup>R<sup>9</sup>), -CN, -NO<sub>2</sub>,

Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 5


$-\text{CO}_2\text{R}^8$ ,  $-\text{CON}(\text{R}^8\text{R}^9)$ ,  $-\text{NCO-R}^8$ , or halogen;  
n6 and n7 each is, independently for each occurrence, 0, 1, or 2;  
wherein said heterocyclyl is azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothio-pyranyl sulfone, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholinyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, piperidyl, piperazinyl, pyridyl, pyridyl N-oxide, quinoxalinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydro-quinolinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiazolyl, thiazolinyl, thienofuryl, thienothienyl, or thienyl; and wherein said aryl is phenyl or naphthyl;

provided that:


either  $\text{R}^6$  is H or  $\text{R}^7$  is =O, -H, or =S wherein when  $\text{R}^6$  is H,



then  $\text{R}^{10}$  and  $\text{R}^7$  are taken together to form  $\text{X}^1\text{X}^2\text{X}^3$ ; or when  $\text{R}^7$  is =O, -H, or =S, then  $\text{R}^{10}$  and  $\text{R}^6$  are taken together








wherein  $X^1$ ,  $X^2$ , and  $X^3$  each is, independently, H, halogen,  $-\text{NO}_2$ ,  $-\text{NCO}-\text{R}^8$ ,  $-\text{CO}_2\text{R}^8$ ,  $-\text{CN}$ , or  $-\text{CON}(\text{R}^8\text{R}^9)$ ; and when  $\text{R}^1$  is  $\text{N}(\text{R}^{24}\text{R}^{25})$ , then  $n_3$  is 1,  $n_4$  and  $n_5$  each is 0,  $Z$  is a bond, and  $\text{R}^3$  and  $\text{R}^{11}$  can be taken together to form




wherein  $n_2$  is 1-6, and  $X^4$  and  $X^5$  each is, independently, H,  $(\text{C}_{1-6})$ alkyl, or aryl, or  $X^4$  and  $X^5$  can be taken together to form  $(\text{C}_{3-6})$ cycloalkyl; or a pharmaceutically acceptable salt thereof.

2 (original) : A compound according to claim 1, wherein:

$\text{R}^1$  is  ,  ,  ,  ,  , or  $\text{N}(\text{R}^{24}\text{R}^{25})$ ; and  $X$  is  $\text{CH}(\text{R}^{11})_{n_3}(\text{CH}_2)_{n_4}$  or  $Z$ , wherein  $Z$  is O, S, or  $\text{N}(\text{R}^{12})$ ; or a pharmaceutically acceptable salt thereof.


3 (withdrawn) : A compound according to claim 2, wherein:

$\text{R}^1$  is  ;  $X$  is  $\text{CH}(\text{R}^{11})_{n_3}(\text{CH}_2)_{n_4}$ ; and  $n_1$  is 0;

Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 7

or a pharmaceutically acceptable salt thereof.

4 (withdrawn): A compound according to claim 2,  
wherein:




$n_3$ ,  $n_4$ , and  $n_5$  each is 0;

$Z$  is a bond;

$Y$  is, independently for each occurrence, CO or CS; and  
 $n_1$  is 0;


or a pharmaceutically acceptable salt thereof.

5 (original): A compound according to claim 2,  
wherein:



$R^6$  is H;

$n_1$  is 1;



$R^7$  and  $R^{10}$  are taken together to form

$n_3$  is 1 and  $R^{11}$  is H;

$Z$  is O or a bond;

$n_5$  is 0; and

$Y$  is CO, CH<sub>2</sub>, or a bond;

or a pharmaceutically acceptable salt thereof.

Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 8

6 (withdrawn): A compound according to claim 2,  
wherein:

$R^1$  is  $N(R^{24}R^{25})$ ;

$n_1$  is 0;


$n_3$  is 1;

$n_4$  is 0;

$n_5$  is 0;


$Y$  is CO or CS;

$Z$  is a bond; and



$R^3$  and  $R^{11}$  are taken together to form or a pharmaceutically acceptable salt thereof.


7 (original): A compound according to claim 2,  
wherein:



$R^1$  is ;

$R^7$  is H or =O;

$n_1$  is 1;



$R^6$  and  $R^{10}$  are taken together to form ;

$n_3$  is 1 and  $R^{11}$  is H;

$n_5$  is 0;

$Y$  is CO or  $CH_2$ ; and

Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 9

Z is O or a bond;  
or a pharmaceutically acceptable salt thereof.

8 (withdrawn): A compound according to claim 3,  
wherein said compound is

8-butyl-7-(3-(imidazol-5-yl)-1-oxopropyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;  
8-butyl-2-(2-hydroxyphenyl)-7-(imidazol-4-yl-propyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;  
8-butyl-7-(4-imidazolylpropyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;  
7-(2-(imidazol-4-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;  
2-(2-methoxyphenyl)-8-(1-methylpropyl)-7-(1-oxo-2-(1-phenylmethyl)-imidazol-5-yl)ethyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;  
2-(2-methoxyphenyl)-8-(1-methylpropyl)-7-(2-(1-phenylmethyl)-imidazol-5-yl)ethyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;  
7-(2-(1-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;  
7-((1H-imidazol-4-yl)methyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;  
7-((4-imidazolyl)carbonyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;  
7-(1-(4-cyanophenylmethyl)-imidazol-5-yl)methyl-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;  
7-(2-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;  
5-butyl-7-(2-(4-cyanophenylmethylimidazol-5-yl)-1-oxo-ethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 10

6-butyl-7-(2-(4-cyanophenylmethylimidazol-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine;

6-butyl-7-(2-(4-cyanophenylmethylimidazol-5-yl)-1-oxo-ethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine;

5-butyl-7-(2-(1-(4-cyanophenylmethyl)-imidazole-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(1-(4-cyanophenylmethyl)-imidazole-5-yl)-1-oxo-ethyl)-8-(cyclohexylmethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

5-butyl-7-(2-(1H-imidazole-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-2-(2-(phenylmethoxy)-phenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine; or

2-(2-butoxyphenyl)-7-(2-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine; or a pharmaceutically acceptable salt thereof.

9 (previously presented): A compound according to claim 5, wherein said compound is

1,2-dihydro-1-((1H-imidazol-4-yl)methyl)-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

9-bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

9-chloro-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 11

10-bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine; or

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-8-fluoro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;  
or a pharmaceutically acceptable salt thereof.

10 (previously presented): A compound according to claim 9, wherein said compound is

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

9-bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

9-chloro-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

10-bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine; or

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-8-fluoro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

or a pharmaceutically acceptable salt thereof.

11 (withdrawn): A compound according to claim 6, wherein said compound is

7-(2-amino-1-oxo-3-thiopropyl)-8-(mercaptoethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine disulfide;

or a pharmaceutically acceptable salt thereof.

Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 12


12 (original): A compound according to claim 7, wherein said compound is

5-(2-(1-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxoethyl)-5,6-dihydro-2-phenyl-1H-imidazo[1,2-a][1,4]benzodiazepine;  
or a pharmaceutically acceptable salt thereof.


13 (original): A compound according to claim 2 wherein said compound is

1,2-dihydro-1-(2-(imidazol-1-yl)-1-oxoethyl)-4-(2-methoxyphenyl) imidazo[1,2a][1,4]benzodiazepine;  
1,2-dihydro-4-(2-methoxyphenyl)-1-(2-(pyridin-3-yl)-1-oxoethyl) imidazo[1,2a][1,4]benzodiazepine; or  
1,2-dihydro-4-(2-methoxyphenyl)-1-(2-(pyridin-4-yl)-1-oxoethyl) imidazo[1,2a][1,4]benzodiazepine;  
or a pharmaceutically acceptable salt thereof.


14 (currently amended): A compound according to claim 2, wherein said compound is




Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 13









Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 14








Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 15



Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 16



Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 17



or a pharmaceutically acceptable salt thereof.

15 (previously presented): A pharmaceutical composition for use in treating a disease selected from the group consisting of breast cancer, colon cancer, pancreas cancer, prostate cancer, lung cancer, ovarian cancer,

Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 18


epidermal cancer and hematopoietic cancer, comprising an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

16 (previously presented): A method of treating a disease in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein said disease is selected from the group consisting of breast cancer, colon cancer, pancreas cancer, prostate cancer, lung cancer, ovarian cancer, epidermal cancer and hematopoietic cancer.






17 (canceled)

18 (canceled)





19 (original): A compound according to claim 2, wherein said compound is



Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 19



Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 20



or a pharmaceutically acceptable salt thereof.

20 (previously presented): A pharmaceutical composition for use in treating a disease selected from the group consisting of fibrosis, benign prostatic hyperplasia,

Inventor : Gordon et al.  
Serial No. : 09/868,356  
Filed : August 10, 2001  
Page : 21

atherosclerosis, restenosis and hepatitis delta virus infection comprising an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

21 (previously presented): A method of treating a disease in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein said disease is selected from the group consisting of fibrosis, benign prostatic hyperplasia, atherosclerosis, restenosis and hepatitis delta virus infection.